Antitumoral effects of vasoactive intestinal peptide in human renal cell carcinoma xenografts in athymic nude mice

We studied antitumor effect of VIP in human renal cell carcinoma (RCC) (A498 cells xenografted in immunosuppressed mice). VIP-treated cells gave resulted in p53 upregulation and decreased nuclear ?-catenin translocation and NFKB expression, MMP-2 and MMP-9 activities, VEGF levels and CD-34 expressio...

Descripción completa

Detalles Bibliográficos
Autores: Vacas Oliva, Eva, Arenas Jiménez, María Isabel|||0000-0002-7825-0654, Muñoz Moreno, Laura|||0000-0002-2322-8986, Bajo Chueca, Ana María|||0000-0002-4944-4222, Sánchez Chapado, Manuel Vicente|||0000-0003-3317-4544, Prieto Villapún, Juan Carlos, Carmena Sierra, María José|||0000-0002-5602-0014
Tipo de recurso: artículo
Fecha de publicación:2013
País:España
Institución:Universidad de Alcalá (UAH)
Repositorio:e_Buah Biblioteca Digital Universidad de Alcalá
Idioma:inglés
OAI Identifier:oai:ebuah.uah.es:10017/59774
Acceso en línea:http://hdl.handle.net/10017/59774
https://dx.doi.org/10.1016/j.canlet.2013.04.033
Access Level:acceso abierto
Palabra clave:VIP
MMP
VEGF
NFKB
ccRCC
Medicina
Medicine
Descripción
Sumario:We studied antitumor effect of VIP in human renal cell carcinoma (RCC) (A498 cells xenografted in immunosuppressed mice). VIP-treated cells gave resulted in p53 upregulation and decreased nuclear ?-catenin translocation and NFKB expression, MMP-2 and MMP-9 activities, VEGF levels and CD-34 expression. VIP led to a more differentiated tubular organization in tumours and less metastatic areas. Thus, VIP inhibits growth of A498-cell tumours acting on the major issues involved in RCC progression such as cell proliferation, microenvironment remodelling, tumour invasion, angiogenesis and metastatic ability. These antitumoral effects of VIP offer new therapeutical possibilities in RCC treatment.

Similares en LA Referencia